Bedrosian Camille Linsider trades
In SEC Form 4 filings, Bedrosian Camille L is listed as Chief Medical Officer of Amylyx Pharmaceuticals, Inc. (AMLX) and Director of Crinetics Pharmaceuticals, Inc. (CRNX). In the last 90 days, Bedrosian Camille L sold $324.9K of Amylyx Pharmaceuticals, Inc. (AMLX) on the open market and bought none.
Companies and roles
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-01
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | Sep 10 | Sep 14 | S | 7,947 | $32.21 | Sale −$256,004 | 280,145 | No | Form 4 |
| AMLXAmylyx Pharmaceuticals, Inc. | Sep 10 | Sep 14 | S | 2,081 | $33.09 | Sale −$68,864 | 278,064 | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 16,300 | $85.00 | $1,385,500 | 5,925 | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 5,925 | $85.00 | $503,625 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 25,000 | $68.92 | $1,723,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 17,500 | $64.77 | $1,133,475 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 17,500 | $66.71 | $1,167,425 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 17,500 | $64.68 | $1,131,900 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 12,500 | $40.29 | $503,625 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 10,350 | $52.67 | $545,135 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 9,730 | $49.13 | $478,035 | not reported | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.